Monopar Therapeutics Inc. announced on December 20, 2024, the pricing of an underwritten registered offering of common stock and a concurrent private placement of pre-funded warrants. The combined gross proceeds are expected to be $40 million.
The registered offering includes 798,655 shares of common stock priced at $23.79 per share. Concurrently, a private placement of pre-funded warrants to purchase 882,761 shares of common stock was priced at $23.789 per pre-funded warrant.
The offering is expected to close around December 23, 2024, subject to customary closing conditions. The net proceeds are intended for general corporate purposes, including research and development, clinical trial expenditures, product manufacturing, and working capital, with participation from key investors such as RA Capital Management and Janus Henderson Investors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.